Cerdulatinib is a small molecule SYK/JAK kinase inhibitor in development for treatment of hematological malignancies.[1] It has lowest nM IC50 values against TYK2, JAK1, JAK2, JAK3, FMS, and SYK.[2]
![]() | |
Clinical data | |
---|---|
Other names | PRT062070, PRT2070, DMVT-502 |
Routes of administration | By mouth |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider |
|
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C20H27N7O3S |
Molar mass | 445.54 g·mol−1 |
3D model (JSmol) | |
| |
|
It is being developed by Portola Pharmaceuticals; in September 2018 the FDA granted orphan drug status to cerdulatinib for the treatment of peripheral T-cell lymphoma (PTCL).[3]
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |